Skip to main content
IMUGENE LIMITED logo

IMUGENE LIMITED — Investor Relations & Filings

Ticker · IMU ISIN · AU000000IMU9 LEI · 984500A5C9KF08EAF248 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,442 across all filing types
Latest filing 2019-07-14 Capital/Financing Update
Country AU Australia
Listing ASX IMU

About IMUGENE LIMITED

https://imugene.com

Imugene Limited is a clinical-stage immuno-oncology company focused on developing immunotherapies to activate the immune system against various cancers. The company’s pipeline features multiple platform technologies, including B-cell activating immunotherapies, oncolytic viruses, and CAR-T cell enhancement therapies. Key clinical candidates include HER-Vaxx, targeting HER2-positive gastric cancer, and PD1-Vaxx, a checkpoint inhibitor immunotherapy. Imugene is also advancing the CF33 oncolytic virus platform, which includes VAXINIA and CHECKvacc, alongside the onCARlytics program. The onCARlytics platform is designed to enable CAR-T cells to target solid tumors by inducing the expression of CD19 on cancer cell surfaces. These programs aim to address unmet needs in oncology by providing targeted, potent, and potentially less toxic alternatives to conventional treatments.

Recent filings

Filing Released Lang Actions
Imugene Enhances Portfolio with Compelling Oncolytic Virus 4 pages 85.1KB
Capital/Financing Update Classification · 95% confidence The document is an ASX announcement from Imugene Ltd regarding the acquisition of Vaxinia Pty Ltd and an exclusive license for an oncolytic virus technology. It details the terms of the license agreement, acquisition conditions, and strategic rationale. There are no financial statements, quarterly or annual results, or detailed financial performance data. The content focuses on a corporate transaction and strategic update rather than financial reporting. The document length is 8937 characters, which is substantial but the content is clearly an announcement of a corporate transaction and licensing deal, not a financial report or earnings release. Therefore, the most appropriate classification is Capital/Financing Update (CAP).
2019-07-14 English
Investor Presentation - Proposed Acquisition 35 pages 7.4MB
Investor Presentation Classification · 95% confidence The document is a detailed presentation about Imugene Limited's proposed acquisition of an oncolytic virus technology called CF33. It includes extensive information about the company, management team, technology background, scientific details, and investment highlights. The content is structured as a presentation with slides, disclaimers, and visuals (not shown here). There is no indication of financial statements, audit information, voting results, or regulatory filings. The document is not a transcript of a call, nor is it a brief factsheet or a legal proceeding update. It is clearly a detailed investor presentation focusing on the company's strategy, technology, and market position related to the acquisition. Therefore, the most appropriate classification is Investor Presentation (IP). The document length (15,000 characters) and content support this classification with high confidence.
2019-07-14 English
Investor update call details 2 pages 316.2KB
Regulatory Filings Classification · 90% confidence The document is an ASX announcement dated 15 July 2019 from Imugene Limited, providing details about an upcoming investor update call scheduled for the same day. It includes dial-in information and a brief company overview. The document does not contain any financial statements, detailed financial analysis, or substantive financial data. It is essentially a notice about a teleconference event for investors rather than a transcript or report. The document length is 2620 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, this document fits best into the category of a Call Transcript announcement or notice. However, since it is only an announcement of the call and not the transcript itself, it does not qualify as a Call Transcript (CT). Given the options, the best fit is Regulatory Filings (RNS) as a general announcement that does not fit other categories specifically.
2019-07-14 English
New HER-Vaxx Cancer Vaccine trial data presented at ESMO GI 2 pages 79.5KB
Regulatory Filings Classification · 90% confidence The document is an ASX announcement presenting new clinical trial data for the HER-Vaxx cancer vaccine. It discusses clinical study results, patient responses, and upcoming publication of the data. The content is focused on announcing new clinical data and study progress rather than providing a full detailed report or financial statements. There is no indication that this is a full Annual Report, Interim Report, or Earnings Release. It is also not a regulatory filing, management change, or voting result. The document is a public announcement of clinical trial data presented at a medical congress, which fits best under a general regulatory announcement category rather than a financial or governance report. Given the nature and length of the document, the best classification is Regulatory Filings (RNS).
2019-07-07 English
Appendix 3B and 708A Notice 15 pages 507.5KB
Capital/Financing Update Classification · 100% confidence The document is titled 'Appendix 3B New issue announcement' and contains detailed information about the issuance of new securities, including shares and unlisted options, their terms, issue prices, and the purpose of the issue. It also includes sections on quotation of securities and compliance with ASX rules, as well as calculations related to placement capacity under ASX rules 7.1 and 7.1A. The document is a formal announcement to the Australian Securities Exchange (ASX) regarding new securities issuance and application for quotation. It does not contain financial statements, management discussion, or audit information, nor is it a transcript or presentation. It is not a report publication announcement but the actual announcement of a capital raising event. Therefore, the document fits the category of Capital/Financing Update (CAP).
2019-06-26 English
Updated Phase 1b HER-Vaxx data presented at ASCO 2 pages 143.2KB
Regulatory Filings Classification · 95% confidence The document is an ASX announcement dated 4 June 2019 from Imugene Limited about updated Phase Ib HER-Vaxx data presented at the American Society of Clinical Oncology 2019 Annual Meeting. It describes clinical trial progress and presentation details at a scientific conference. The document is relatively short (4372 characters) and serves as a news release or update rather than a detailed financial or regulatory report. It does not contain financial statements, management discussion, or regulatory compliance information. It is not an earnings release or annual/interim report. It is an announcement of clinical trial data presentation, which fits best under the category of a Regulatory Filing (RNS) as a general regulatory announcement or company update that does not fit other specific categories.
2019-06-03 English

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.